Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Novel Predictive Strategy Using CA19-9 and Fecal Elastase Levels to Make Treatment Decisions for Resectable Pancreatic Cancer; Retrospective Study

NCT05923567 is registered in ClinicalTrials.gov with Gangnam Severance Hospital as lead sponsor.

NCT NCT05923567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05923567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Novel Predictive Strategy Using CA19-9 and Fecal Elastase Levels to Make Treatment Decisions for Resectable Pancreatic Cancer; Retrospective Study
Lead sponsor
Gangnam Severance Hospital
Phase
Observational
Overall status
Unknown status
Start date
February 18, 2021
Completion date
December 31, 2024
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

paancreatic cancer